Barber et al. just published a fundamentally flawed study on diabetes medicines in JAMA Network Open (JNO). This study wrongly suggests that cost-based pricing accurately values innovative on-patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results